Mina Hosseini
LightNews LightNews
minacompetition.bsky.social
Mina Hosseini
@minacompetition.bsky.social
350 followers 610 following 8 posts
Legal Academic and Consultant | PhD in Competition Law | Health Law and Policy | Pharmaceutical Law and Policy | AI in Healthcare | Marie Curie Alumna| UCD
www.minahosseini.com
Posts Replies Media Videos
Reposted by Mina Hosseini
maryjguy.bsky.social
Delighted to see this Symposium of @jlme-journal.bsky.social on Public Health, Markets, and Law is now out.

Many thanks to @minacompetition.bsky.social and Imelda Maher!

My article considers #hospitals #stateaid and #SGEI

www.cambridge.org/core/journal...
September 15, 2025 at 2:35 PM
Reposted by Mina Hosseini
jlme-journal.bsky.social
The September issue of the Journal of Law, Medicine & Ethics is now online.

This issue features the open-access symposium Public Health, Markets, and Law, guest edited by @minacompetition.bsky.social and Imelda Maher, with incisive, in-depth articles.

Read now: www.cambridge.org/core/journal...
September 15, 2025 at 4:11 PM
Reposted by Mina Hosseini
jlme-journal.bsky.social
New open-access on FirstView: "EU’s Extraterritorial Obligations for Global Medicine Access Under the Convention on the Rights of Persons with Disability (CPRD)" by
‪@katperehudoff.bsky.social‬ from special issue "Public Health, Markets, and Law." #DisabilityRights
www.cambridge.org/core/journal...
Symposium Articles EU’s Extraterritorial Obligations for Global Medicine Access Under the Convention on the Rights of Persons with Disability (CPRD) Katrina Perehudoff1,2,3,4,5 1University of Amsterdam Amsterdam Law School, Law for Health and Life, Netherlands; 2Amsterdam Institute for Global Health and Development, Netherlands; 3Amsterdam Centre for European Studies, University of Amsterdam; 4Amsterdam Centre for European Law and Governance, University of Amsterdam and 5Medicines Law & Policy, Amsterdam, the Netherlands Abstract Equitable access to medicines is vital for people with disabilities to receive effective, affordable, and quality treatment, helping preserve functionality, prevent further disability, and promote social and economic inclusion. This paper explores the specific medicine needs of people with disabilities in low- and middle-income countries (LMICs), focusing on the European Union’s (EU) extraterritorial legal obligations under the Convention on the Rights of Persons with Disabilities (CRPD). As the first regional international organization to accede to a UN human rights treaty, the EU offers a unique case for examining how international legal commitments extend beyond its borders. The paper outlines a legal framework based on the CRPD to assess the EU’s responsibilities for ensuring access to medicines globally. This framework is applied to two case studies: the EU’s internal joint COVID-19 vaccine procurement strategy and its external BioNTainer initiative for vaccine production in Africa under Team Europe. The analysis finds that the EU falls short of its CRPD obligations, particularly in areas of technology transfer and intellectual property sharing, which are essential for equitable global vaccine access. The paper concludes that the EU’s current actions do not fulfill its human rights commitments to people with disabilities in LMICs. Keywords: access to medicines; disability rights; pharmaceuticals; European Union; intellectual property
September 3, 2025 at 9:00 PM
Reposted by Mina Hosseini
euhealthgov.bsky.social
Day 2 #UACES2025 saw our 3rd panel on data exclusivity vouchers, global health, wellness devices, and solidarity in European healthcare!

Many thanks to Paula Dornbusch, Ian Manners, Federica Casarosa and Mary Guy
September 3, 2025 at 11:14 AM
Reposted by Mina Hosseini
euhealthgov.bsky.social
Our final panel at #UACES2025 considered the balance between health and other EU policies - ethics, trade, alcohol brand marketing, and AI.

Many thanks to Juan Collado Perez Llantada, @merikoivusalo.bsky.social, Jaydon Souter, and Phil Ryan!
September 3, 2025 at 11:19 AM
Reposted by Mina Hosseini
euhealthgov.bsky.social
We’re having a great time at #UACES2025!

Day 1 included presentations on complexity, Covid-19, competition law, cross-border telemedicine and forced migrants’ access to health and healthcare

Many thanks @eleanorbrooks.bsky.social @minacompetition.bsky.social @mechthildroos.bsky.social & others!
September 2, 2025 at 9:45 AM
Reposted by Mina Hosseini
maryjguy.bsky.social
Grand #UACES2025 walking tour of Liverpool this afternoon - taking in reconciling the city’s slave trade history, football, and a certain boyband…

Thanks Lauren for the group photo!
August 31, 2025 at 7:54 PM
Reposted by Mina Hosseini
deruijter.bsky.social
With @PramitiParwani & @katperehudoff.bsky.social, we explored EU pharma regulators’ role in access to medicines in low-income countries. Trust remains one-way, reinforcing dependencies; building regional regulatory capacity is key for global health 💫
jlme-journal.bsky.social The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Aug 13
New open access on FirstView: "Trust Beyond Borders: European External Regulatory Influence on Access to Medicines" by Pramiti Parwani, ‪@katperehudoff.bsky.social‬, and @deruijter.bsky.social from the upcoming fall special issue "Public Health, Markets, and Law."
www.cambridge.org/core/journal...
Symposium Articles Trust Beyond Borders: European External Regulatory Influence on Access to Medicines Pramiti Parwani1,2,3 , Katrina Perehudoff1,2,3 and Anniek de Ruijter1,2 1University of Amsterdam, Amsterdam Law School, Law for Health and Life, Netherlands; 2Amsterdam Institute for Global Health and Development, Netherlands and 3Amsterdam Centre for European Law and Governance, University of Amsterdam, Netherlands Abstract European institutions are widely recognized as wielding regulatory power in a globalized market, exporting its standards across borders and between sectors. This paper asks what institutional dynamics catalyze European external regulatory impact on pharmaceutical governance in low- and middle-income countries (LMICs). The research focuses on two European regulatory bodies, the European Medicines Agency (EMA) and the European Patent Office (EPO), and explores the dynamics of their technocratic outreach beyond European borders. We find that trust is a key underlying institutional dynamic facilitating some forms of European external relations. The agencies extend their influence through technical assistance, collaboration, and work-sharing with LMIC regulators, fostering a one-sided relationship of“technocratic trust.” This trust, reinforced by international regulatory frameworks that position the EMA and EPO as“trustworthy” regulators, enables these agencies to expand their regulatory influence beyond Europe. By critically examining the impact of this trust-building on LMICs’ regulatory autonomy, this research contributes to the broader discourse on European regulatory power in global health governance and highlights potential implications for pharmaceutical markets and access in LMICs. Keywords: European Regulatory Bodies; Pharmaceuticals Access; European Medicines Agency (EMA); European Patent Office (EPO); Trust
August 14, 2025 at 7:59 AM
Reposted by Mina Hosseini
jlme-journal.bsky.social
New open access on FirstView: "Trust Beyond Borders: European External Regulatory Influence on Access to Medicines" by Pramiti Parwani, ‪@katperehudoff.bsky.social‬, and @deruijter.bsky.social from the upcoming fall special issue "Public Health, Markets, and Law."
www.cambridge.org/core/journal...
Symposium Articles Trust Beyond Borders: European External Regulatory Influence on Access to Medicines Pramiti Parwani1,2,3 , Katrina Perehudoff1,2,3 and Anniek de Ruijter1,2 1University of Amsterdam, Amsterdam Law School, Law for Health and Life, Netherlands; 2Amsterdam Institute for Global Health and Development, Netherlands and 3Amsterdam Centre for European Law and Governance, University of Amsterdam, Netherlands Abstract European institutions are widely recognized as wielding regulatory power in a globalized market, exporting its standards across borders and between sectors. This paper asks what institutional dynamics catalyze European external regulatory impact on pharmaceutical governance in low- and middle-income countries (LMICs). The research focuses on two European regulatory bodies, the European Medicines Agency (EMA) and the European Patent Office (EPO), and explores the dynamics of their technocratic outreach beyond European borders. We find that trust is a key underlying institutional dynamic facilitating some forms of European external relations. The agencies extend their influence through technical assistance, collaboration, and work-sharing with LMIC regulators, fostering a one-sided relationship of“technocratic trust.” This trust, reinforced by international regulatory frameworks that position the EMA and EPO as“trustworthy” regulators, enables these agencies to expand their regulatory influence beyond Europe. By critically examining the impact of this trust-building on LMICs’ regulatory autonomy, this research contributes to the broader discourse on European regulatory power in global health governance and highlights potential implications for pharmaceutical markets and access in LMICs. Keywords: European Regulatory Bodies; Pharmaceuticals Access; European Medicines Agency (EMA); European Patent Office (EPO); Trust
August 13, 2025 at 2:10 PM
Reposted by Mina Hosseini
jlme-journal.bsky.social
New open-access on FirstView: "Abuse of Dominant Position, Effective Judicial Protection and Abuse of Procedure" by Carmen de Vivero de Porras and Enrique Sanjuán y Muñoz analyzes the attempt to keep a generic alternative to NuvaRing out of the market.
www.cambridge.org/core/journal...
Symposium Articles Abuse of Dominant Position, Effective Judicial Protection and Abuse of Procedure Carmen de Vivero de Porras and Enrique Sanjuán y Muñoz School of Law, University of Malaga, Spain Abstract On October 21, 2022, the Spanish Competition Agency (CNMC) sanctioned the North American pharmaceutical company Merck Sharp & Dohme for abuse of a dominant position. The practice for which it was finally sanctioned consisted of the adoption of a strategy aimed at delaying and making it difficult for another company to enter the Spanish medicines market in order to protect sales for a product marketed exclusively by that company and for which had a patent. This paper analyzes this resolution in an attempt to delimit the difference between the legitimate exercise of the right to effective judicial protection and its abuse. Keywords: competition; strategy; medicines market; dominant position; market
July 30, 2025 at 1:48 PM
Reposted by Mina Hosseini
susigeiger.bsky.social
Fascinated by #ElizabethHolmes of #Theranos and her wild journey from digital health entrepreneur heroine to villaine and #Girlboss? Asking yourself in whose interest it all happened? So were we!

@keanbirch.bsky.social @provokedeconomy.bsky.social @allartmarkets.bsky.social you might like this one
orgstudies.bsky.social Organization Studies @orgstudies.bsky.social · Jul 29
𝗗𝗼𝘄𝗻𝗳𝗮𝗹𝗹, 𝗖𝗮𝘁𝗵𝗮𝗿𝘀𝗶𝘀 𝗮𝗻𝗱 𝗥𝗲-𝗴𝗲𝗻𝗱𝗲𝗿𝗶𝗻𝗴: 𝗘𝗻𝘁𝗿𝗲𝗽𝗿𝗲𝗻𝗲𝘂𝗿𝗶𝗮𝗹 𝗴𝗹𝗼𝗿𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗰𝗮𝘀𝗲 𝗼𝗳 𝗧𝗵𝗲𝗿𝗮𝗻𝗼𝘀’ 𝗘𝗹𝗶𝘇𝗮𝗯𝗲𝘁𝗵 𝗛𝗼𝗹𝗺𝗲𝘀.

𝗦𝘂𝘀𝗶 𝗚𝗲𝗶𝗴𝗲𝗿, University College Dublin, Ireland
𝗞𝗮𝘁𝗲 𝗞𝗲𝗻𝗻𝘆, University of Galway, Ireland

doi.org/10.1177/0170...
July 29, 2025 at 1:48 PM
Reposted by Mina Hosseini
maryjguy.bsky.social
Proud to share this new publication on #hospitals #stateaid and #SGEI in the excellent Symposium on “Public Health, Markets, and Law” with @jlme-journal.bsky.social
edited by Dr Mina Hosseini and Imelda Maher.

Some key findings follow!

www.cambridge.org/core/journal...
On The Quiet Power of National Decisions: Hospitals, State Aid, and Services of General Economic Interest | Journal of Law, Medicine & Ethics | Cambridge Core
On The Quiet Power of National Decisions: Hospitals, State Aid, and Services of General Economic Interest
www.cambridge.org
July 25, 2025 at 6:53 AM
Reposted by Mina Hosseini
jlme-journal.bsky.social
New open access article on FirstView: "Competition Law and Ethics of Innovation as Catalysts for Fairness: Reimagining the EU’s COVID-19 Vaccine Strategy" by @minacompetition.bsky.social, part of the upcoming symposium "Public Health, Markets and Law."
www.cambridge.org/core/journal...
Symposium Articles Competition Law and Ethics of Innovation as Catalysts for Fairness: Reimagining the EU’s COVID-19 Vaccine Strategy Mina Hosseini Sutherland School of Law, University College Dublin, Ireland Abstract The“EU Vaccines Strategy” launched by the European Commission in June 2020 aimed to ensure vaccine safety, equitable access, affordability, swift distribution, and global solidarity for COVID-19 vaccines. This study critiques the Commission’s centralized procurement approach, focusing on Advance Purchase Agreements (APAs) through a literature review, policy analysis, and a case study of the EU-AstraZeneca’s APA. It identifies critical challenges, including transparency deficits, accountability gaps, and anticompetitive practices by vaccine producers that undermine equitable access. Drawing on these insights, the study proposes the FACER Framework— Fairness, Accountability, Competition Law, Ethics of Innovation, and Resilience— a novel model integrating the Treaty on the European Union (TEU) and the Treaty on the Functioning of the European Union (TFEU) oversight with ethical principles. By embedding legal and moral accountability, FACER offers EU policymakers a robust tool to enhance vaccine strategy and equity in future health crises. Keywords: Pharmaceutical Procurement; EU Vaccines Strategy; Advance Purchase Agreements; Competition Law; Ethics of Innovation
July 25, 2025 at 1:09 PM
Reposted by Mina Hosseini
maryjguy.bsky.social
Great to see this new article by
@minacompetition.bsky.social in @jlme-journal.bsky.social!

www.cambridge.org/core/journal...
July 23, 2025 at 7:45 PM
minacompetition.bsky.social
Delighted to see the first paper from our Symposium “Public Health, Markets and Law” co-edited with Professor Imelda Maher now published in @jlme-journal.bsky.social @ucdschooloflaw.bsky.social @ucddublin.bsky.social
jlme-journal.bsky.social The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Jul 21
New open access: "Rupturing the Temporality of Pharmaceutical Patents: A Sketch for a New Temporal Economy of Pharmaceutical Markets" by @susigeiger.bsky.social has solutions for the broken pharmaceutical patent system. www.cambridge.org/core/journal... #PharmaceuticalMarkets #Pharmaceuticals
Symposium Articles Rupturing the Temporality of Pharmaceutical Patents: A Sketch for a New Temporal Economy of Pharmaceutical Markets Susi Geiger College of Business, University College Dublin, Ireland Abstract The objective of this paper is to devise a set of principles and practices that can break with the temporalities of current pharmaceutical markets, and on this basis sketch a social contract for a new (temporal) political economy of pharmaceuticals. Pharmaceutical futures are, in my analysis, doubly predetermined by standard arguments around pharmaceutical patenting and pricing: they are narrated as a consequence of“past” investments to be recouped, but they are also predetermined on a particular“future perfect,” where past investment successes and promises to maintain the status quo determine the course of action of future investors. This double colonization of the future, in my analysis, eliminates any scope for meaningful change. Making this often implicit temporality of pharmaceutical markets explicit may allow to better take into account multiple temporalities in regulating this space. Chiefly among them are patients’ temporalities, which typically get overridden by the peculiar timelines of patent-based markets. The mRNA vaccine market serves as an illustration of the theoretical arguments raised, and I discuss four strategies that could lead toward a new temporal political economy of pharmaceutical markets: temporally sensitive policymaking; decolonizing the future through narrower patents; delinking patents from their asset condition; and pharmaceutical commons. Keywords: pharmaceutical markets; mRNA technology; patents; temporality; political economy of pharmaceuticals; pharmaceutical asset; pharmaceutical commons; future; temporal policymaking; delinkage
July 21, 2025 at 6:14 PM
Reposted by Mina Hosseini
lawhealthlife.bsky.social
Mahsa Shabani from Law for Health and Life contributed to Future-AI’s global guidelines for trustworthy AI in healthcare—now published in The BMJ! A major step toward safer, ethical AI.

🔗 Read more: https://bit.ly/4i4RN9d
Future-AI Consortium Tackle Trustworthy AI in Healthcare - LHL
We are excited to announce that Mahsa Shabani from the Law Centre for Health and Life is part of the pioneering Future-AI consortium.
bit.ly
February 24, 2025 at 6:19 PM
Reposted by Mina Hosseini
coerciveinjustice.bsky.social
#CoerciveInJustice is now online! 🛜 Check out our new website: www.coerciveinjustice.com to learn about the research project, meet the team, and catch up on all the latest news and events.
January 31, 2025 at 7:51 AM
Reposted by Mina Hosseini
audreymplan.bsky.social
‼️ CALL FOR PAPERS - ECRs IN IRELAND/UK ‼️

Save an #ECR, spread with your network 😉

▶️"'Law and...' Reflections on interdisciplinarity and the law from ECAs in 🇮🇪 & 🇬🇧"

📆Dublin, Jun 12th 2025

⏰Submissions Deadline: Apr 1st 2025
January 29, 2025 at 9:45 AM
Reposted by Mina Hosseini
grabaranowska.bsky.social
Thinking about applying for a Marie Curie fellowship this year?

Join Cathryn Costello, @liliantsourdi.bsky.social, @minacompetition.bsky.social, Violeta Moreno-Lax and me next Tuesday at 12:00 CET.
hertiecfr.bsky.social Centre for Fundamental Rights - Hertie School @hertiecfr.bsky.social · Feb 5
Are you:
🔹 Applying for a Marie Skłodowska-Curie Postdoc Fellowship?
🔹 Looking for mentors or a host institution?
Join our webinar & learn from the best! 🔗 tinyurl.com/mvvfawac
Webinar: Marie Skłodowska-Curie Postdoctoral Fellowships
Join us for a discussion of Marie Skłodowska-Curie Postdoctoral Fellowships
tinyurl.com
February 11, 2025 at 3:32 PM
minacompetition.bsky.social
Delighted that our article with Imelda Maher has been nominated for Concurrences 2025 Antitrust Writing Awards. Vote for us here: awards.concurrences.com/en/awards/20...
January 13, 2025 at 4:55 PM
Reposted by Mina Hosseini
euhealthgov.bsky.social
Hello BlueSky!

We’re EUHealthGov- here for EU health law and policy, working with academics, policymakers, practitioners…

Check out our website for information about our events

www.euhealthgov.org
EU Health Governance Network – A network of professionals interested in EU health law and policy
www.EUHealthGov.org
December 9, 2024 at 7:27 PM
Reposted by Mina Hosseini
madhupai.bsky.social
Two wonderful global health scholars have made their global health books free to download

Bravo and thanks @seyeabimbola.bsky.social and
@thewrittenro.bsky.social

The Foreign Gaze:
www.editions.ird.fr/open_access_...

Rethinking Global Health:
taylorfrancis.com/books/oa-mon...
December 7, 2024 at 10:33 PM
minacompetition.bsky.social
Published today in Constitutional Discourse My New blog post: "Of Disparagement & Other Demons: Trends in EU Competition Law Enforcement in the Pharmaceutical Sector "

constitutionaldiscourse.com/of-disparage...

Part of my #MSCA project #COMPHACRISIS #EUAntitrust #Pharma #Health #Disparagement
Of Disparagement and Other Demons: Trends in EU Competition Law Enforcement in the Pharmaceutical Sector - Constitutional Discourse
Disparagement practices (spreading misleading information to undermine competitors’ products) as an anti-competitive practice in the pharmaceutical sector is not a new topic in EU competition law. How...
constitutionaldiscourse.com
November 27, 2024 at 11:06 AM
minacompetition.bsky.social

I am happy that our chapter with Imelda Maher, 'Competition Law Institutions and Future Challenges,' has just been published as part of the landmark collection, Why Competition, by Concurrences. @ucdschooloflaw.bsky.social
November 22, 2024 at 5:18 PM
Reposted by Mina Hosseini
uaces.bsky.social
The Call for Papers for the UACES 55th Annual Conference 2025 at Liverpool John Moores University is officially open!

Join us from 31 August to 3 September 2025, to explore Europe’s resilience in a changing world.

Submit your paper by 26 January 2025 👉 www.conftool.org/uaces2025/

#CfP #UACES2025
November 18, 2024 at 11:00 AM